Marker Therapeutics is a clinical-stage immuno-oncology company developing MAR-T (Multi Antigen Recognizing T) cell therapies, which are non-genetically engineered T cell immunotherapies designed to treat hematological malignancies and solid tumors by expanding natural tumor-specific T cells to recognize multiple tumor-associated antigens. The company's platform includes two primary candidates: MT-601, an autologous therapy targeting six antigens for lymphoma and pancreatic cancer, and MT-401-OTS, an off-the-shelf therapy manufactured from healthy donor inventory for rapid deployment in acute myeloid leukemia and myelodysplastic syndrome. Marker generates revenue through licensing agreements—it holds exclusive worldwide rights to the MAR-T technology from Baylor College of Medicine with tiered royalty obligations and potential milestone payments—and is supported by government grants from the Cancer Prevention & Research Institute of Texas and the National Institutes of Health, while advancing clinical trials toward potential commercialization.